Kotoko Yamatani 研究室

AI 要約（直近 5 年の研究成果）

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

研究成果（14 件）

• [2025] PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML
  DOI: https://doi.org/10.1016/j.bneo.2025.100121
• [2024] Decitabine-Venetoclax Treatment Reactivates Endogenous Retrovirus RNA Signaling in AML Cells and Induces T Cell Activation
  DOI: https://doi.org/10.1182/blood-2024-202722
• [2023] PPARG and ASS1: Targets of Metabolic Alteration in Venetoclax / Decitabine Resistant Acute Myeloid Leukemia
  DOI: https://doi.org/10.1182/blood-2023-178554
• [2022] Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML
  DOI: https://doi.org/10.1016/j.tranon.2022.101354
• [2022] Meals and Room Temperature Storage do not Significantly Affect Feasibility of Direct RT-PCR Tests for SARS-CoV-2 Using Saliva
  DOI: https://doi.org/10.7754/clin.lab.2021.210451
• [2022] Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses
  DOI: https://doi.org/10.1182/blood-2022-156999
• [2021] SARS-CoV-2 seroprevalence in healthcare workers at a frontline hospital in Tokyo
  DOI: https://doi.org/10.1038/s41598-021-87688-9
• [2021] Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests
  DOI: https://doi.org/10.1371/journal.pone.0246536
• [2021] Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests
• [2021] Diverse Mechanisms of Resistance to Decitabine and Venetoclax Therapy in Newly Diagnosed and Relapsed/Refractory AML Inferred By Transcriptome Analysis
  DOI: https://doi.org/10.1182/blood-2021-149432

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。